U.S. Software Stock News

NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND): Taking Stock of Valuation After Recent Share Price Pullback

Grindr (GRND) has quietly drifted this month, but its longer track record, including a strong 3 year return, makes the current pullback worth a closer look for patient, risk tolerant investors. See our latest analysis for Grindr. The stock has bounced 6.2 percent on a 7 day share price return, but that sits against a weaker year to date share price trend and a still impressive 3 year total shareholder return. This suggests momentum has cooled while the longer term growth story remains...
NYSE:MHK
NYSE:MHKConsumer Durables

Is Mohawk Industries Attractively Priced After Housing Cycle Weakness in 2025?

If you have been wondering whether Mohawk Industries at around $108 a share is a bargain or a value trap, you are not alone. This article is designed to cut through the noise and focus squarely on what the numbers say. The stock is down about 2.6% over the last week, roughly 1.2% over the last month, and about 6.3% year to date, while still sitting on a 10.8% gain over three years despite a 22.7% slide over five years. Recent headlines have centered on the housing and renovation cycle,...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

How Completion of REVITALYZ Enrollment and Orphan Status at Avadel Pharmaceuticals (AVDL) Has Changed Its Investment Story

Avadel Pharmaceuticals has completed patient enrollment in REVITALYZ, its Phase 3 trial testing once-at-bedtime LUMRYZ for idiopathic hypersomnia, advancing the drug beyond its existing US FDA-approved use in narcolepsy. This milestone, paired with LUMRYZ’s Orphan Drug Designation in idiopathic hypersomnia, could meaningfully influence expectations for the drug’s long-term role in sleep medicine. We’ll now explore how completion of REVITALYZ enrollment, and the prospect of label expansion...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug

Innoviva, Inc. recently received US FDA approval for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients. This marks one of the first new FDA-approved treatments for gonorrhea in nearly twenty years, underscoring Innoviva’s role in addressing antibiotic resistance and unmet infectious disease needs. We’ll now explore how bringing a first-in-class, single-dose oral treatment for gonorrhea affects...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

3 Undervalued Small Caps With Insider Action Across Global Markets

As the U.S. market experiences a resurgence with major stock indexes closing sharply higher for the second consecutive day, small-cap stocks are gaining attention amid this renewed risk appetite. In this dynamic environment, identifying promising small-cap opportunities involves looking at companies with solid fundamentals and potential growth catalysts that align well with current market trends.
NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

Undervalued Equities That May Offer Value In December 2025

As the U.S. stock market experiences a resurgence with major indexes posting gains, driven by a rally in tech stocks, investors are increasingly looking for opportunities that may be undervalued. In this environment of renewed risk appetite and shifting sector performances, identifying stocks that offer strong fundamentals at attractive valuations becomes crucial for those seeking potential value in their portfolios.
NYSE:SE
NYSE:SEMultiline Retail

Li Auto And 2 More Growth Companies With Strong Insider Confidence

As the U.S. stock market experiences a resurgence, with major indexes like the S&P 500 and Nasdaq posting weekly gains amid a tech rally, investor confidence appears to be on the rise. In such an environment, growth companies with high insider ownership can signal strong internal belief in their long-term potential, making them attractive considerations for those looking to align with management's vision.
NYSE:DDL
NYSE:DDLConsumer Retailing

Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

As of December 19, 2025, major stock indexes in the United States have shown a notable upswing, with the tech-heavy Nasdaq and benchmark S&P 500 posting weekly gains amid a continued rally in technology shares. This positive momentum in broader markets can create an intriguing backdrop for exploring investment opportunities across various sectors. Penny stocks, while often considered speculative due to their lower price points and smaller company profiles, remain relevant as they can offer...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Reassessing Lantheus Holdings After a 27.6% Slide and Recent Share Price Rebound

Wondering if Lantheus Holdings is quietly turning into a bargain, or if the market already sees something you do not? Let us break down what the recent numbers are really saying about its value. The stock is down 27.6% over the last year and 25.8% year to date, but it has bounced 18.1% in the last month, a pattern that often signals investors are rethinking the story. That shift in sentiment comes as Lantheus continues to build on its diagnostics and radiopharmaceutical portfolio, including...